.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Moodys
US Department of Justice
Accenture
Julphar
Medtronic
US Army
AstraZeneca
Cantor Fitzgerald
Farmers Insurance

Generated: September 25, 2017

DrugPatentWatch Database Preview

BROVANA Drug Profile

« Back to Dashboard

Which patents cover Brovana, and when can generic versions of Brovana launch?

Brovana is a drug marketed by Sunovion and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirteen countries.

The generic ingredient in BROVANA is arformoterol tartrate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the arformoterol tartrate profile page.

Summary for Tradename: BROVANA

Patents:12
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list41
Clinical Trials: see list14
Patent Applications: see list4,968
Drug Prices:see details
DailyMed Link:BROVANA at DailyMed

Pharmacology for Tradename: BROVANA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: BROVANA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for BROVANA

Drugname Dosage Strength RLD Submissiondate
arformoterol tartrateInhalation SolutionEq. 0.015 mg base/2 mLBrovana10/1/2009

Non-Orange Book Patents for Tradename: BROVANA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,114,912Bronchodilating .beta.-agonist compositions and methods► Subscribe
6,268,533 Formoterol process► Subscribe
7,732,641Formoterol tartrate process and polymorph► Subscribe
7,479,572Formoterol tartrate process and polymorph► Subscribe
7,964,753Formoterol tartrate process and polymorph► Subscribe
7,342,132Formoterol tartrate process and polymorph► Subscribe
9,730,890Bronchodilating beta-agonist compositions and methods► Subscribe
8,623,922Bronchodilating Beta-agonist compositions and methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BROVANA

Country Document Number Estimated Expiration
European Patent Office1660035► Subscribe
Slovenia1381346► Subscribe
Japan2002527364► Subscribe
Portugal1082293► Subscribe
Japan2004532217► Subscribe
Canada2333004► Subscribe
Denmark1446380► Subscribe
Australia5175598► Subscribe
Australia2002349914► Subscribe
Portugal938467► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Chubb
Harvard Business School
Moodys
Julphar
Medtronic
Cipla
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot